Search Within

Even Holth Rustad

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (17)
  3. Review (5)
  4. Research Letter (3)
Groups
  1. Sloan Kettering Institute Postdocs (43)
  2. Department of Medicine (42)
  3. Hematologic Malignancies, Division of (42)
  4. Center for Hematologic Malignancies (38)
  5. Myeloma (38)
  6. Hematologic Malignancies Research (36)

More Groups

People
  1. Carl Landgren (35)
  2. Malin Hultcrantz (30)
  3. Venkata Yellapantula (28)
  4. Francesco Maura (25)
  5. Elli Papaemmanuil (18)
  6. Sham Mailankody (16)

More People

Years
  1. 2021 (8)
  2. 2020 (17)
  3. 2019 (13)
  4. 2018 (5)
Publications
  1. Blood (15)
  2. Best Practice and Research: Clinical Haematology (3)
  3. Blood Cancer Journal (3)
  4. JAMA Oncology (3)
  5. Nature Communications (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Nature Publishing Group (8)
  3. Elsevier Inc. (4)
  4. American Association for Cancer Research (3)
  5. American Medical Association (3)
  6. Elsevier Science, Inc. (3)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
    Journal Article

    Ziccheddu, B.; Biancon, G.; Bagnoli, F.; De Philippis, C.; Maura, F.; Rustad, E. H.; Dugo, M.; Devecchi, A.; De Cecco, L.; Sensi, M.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Moving from cancer burden to cancer genomics for smoldering myeloma: A review
    Review

    Maura, F.; Bolli, N.; Rustad, E. H.; Hultcrantz, M.; Munshi, N.; Landgren, O.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Genomic profiling of multiple myeloma: New insights and modern technologies
    Review

    Hultcrantz, M.; Yellapantula, V.; Rustad, E. H.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Reconstructing the evolutionary history of multiple myeloma
    Review

    Maura, F.; Rustad, E. H.; Boyle, E. M.; Morgan, G. J.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Monitoring minimal residual disease in the bone marrow using next generation sequencing
    Review

    Rustad, E. H.; Boyle, E. M.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Plasma cell myeloma residual disease quantitation using a next-generation sequencing-based IGH clonal rearrangement assay with the aid of a "spike-in" clonal sequence
    Meeting Abstract

    Ho, C.; Syed, M.; Yu, W.; Petrova-Drus, K.; Yao, J. J.; Moung, C.; Chang, J.; Benhamida, J.; Vanderbilt, C.; Roshal, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Revealing the impact of recurrent and rare structural variations in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Yellapantula, V.; Glodzik, D.; Gundem, G.; Leongamornlert, D. A.; Campbell, P. J.; Papaemmanuil, E.; Landgren, O.; Maura, F.
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save